Statins recommended for persons with HIV with a 10-year ASCVD risk score of 5 percent or higher; favored for those with risk score <5 percent
By Elana Gotkine HealthDay Reporter
THURSDAY, May 29, 2025 (HealthDay News) — In a clinical guideline issued by the American College of Physicians and published online May 27 in the Annals of Internal Medicine, recommendations are presented for the use of statins among persons with HIV (PWH).
Craig Beavers, Pharm.D., from the University of Kentucky College of Pharmacy in Lexington, and colleagues developed statin therapy recommendations for PWH. A writing group of 10 members was convened; data were reviewed from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), other studies, and current guidelines.
The U.S. Department of Health and Human Services Panel for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (ARV Guidelines Panel) issued strong recommendations for initiation of statin therapy among PWH with a 10-year atherosclerotic cardiovascular disease (ASCVD) risk score of 5 percent or higher, who derived the greatest benefit from statins in REPRIEVE. The panel favored statins for patients with a 10-year ASCVD risk score below 5 percent, but recommended patient-clinician risk discussions that accounted for additional HIV-related risk factors that could potentially increase ASCVD risk.
“There remain important clinical questions in the management of CVD risk among PWH, including further improvements in risk stratification, as well as additional ASCVD prevention strategies focused on reducing residual risk associated with inflammation,” the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Editorial (subscription or payment may be required)
Copyright © 2025 HealthDay. All rights reserved.
